KCT0003924
Recruiting
未知
PET imaging of prostate cancer using [F-18]Florastamin for pharmacokinetics study: Microdose PET clinical trial
Korea Cancer Center Hospital0 sites6 target enrollmentTBD
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Korea Cancer Center Hospital
- Enrollment
- 6
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\# Prostate cancer patients
- •1\. Histologically diagnosed prostate cancer patient
- •\- diagnosed with prostate cancer with a biopsy
- •\- patient with an elevated prostate\-specific antigen (PSA) after prostatectomy or radiation treatment
- •\- Clinically confirmed with the progression of prostate cancer
- •2\. Able to provide informed consent and have signed an approved consent form that conforms to institutional guidelines to ensure compliance
- •3\. Men with age \=/\> 19 years
- •4\. ECOG (Eastern Cooperative Oncology Group) Performance scale \=2
- •5\. The life expectancy of greater than or equal to 12 months.
- •6\. Those who satisfy the following conditions in a blood test
Exclusion Criteria
- •1\. A person who is judged to be difficult to perform a clinical trial due to a serious medical condition
- •2\. The person who is determined to have a mental disorder that is difficult to perform PET (Positron Emission Tomography) scan
- •3\. Those participating in other clinical trials at screening and participating in clinical trials should be able to influence the acquisition of \[F\-18]Florastamin PET (Positron Emission Tomography) images from the time of registration until the end of the study, or that may affect the safety assessment following intravenous injection of \[F\-18]Florastamin (For example, if you are participating in another cohort\-based trial that is simply focused on monitoring that you do not receive medicines during screening, you can participate in the current clinical trials.)
- •4\. Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
- •5\. Vulnerable subjects (researchers or students who participated in the research, family members, researchers or students of researchers participating in the research)
- •6\. A normal subject whose PSA result is not within the normal range of:
- •\- Less than 40 years: 1\.4ng/ml or lower, 40\-49 years: 2\.0ng/ml or lower, 50\-59 years: 3\.1ng/ml or lower, 60\-69 years: 4\.1ng/ml or lower, 70years or older: 4\.4ng/ml or less
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancer: Phase I clinical trialKCT0004817FutureChem10
Not yet recruiting
Not Applicable
The PSMA-PET scan: a study on tracer properties and test repeatability(metastasized) prostate cancer(gemetastaseerde) prostaatkankerNL-OMON24408VU University Medical Center, Amsterdam20
Completed
Phase 3
Prostate Cancer Imaging with [18Flourine]Prostate Specific Membrane Antigen (PSMA) PET: a study on pharmacokinetics and test repeatabilityprostate cancerprostate malignancyneoplasm of the prostate10038597NL-OMON45317Vrije Universiteit Medisch Centrum20
Active, not recruiting
Phase 1
Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11prostatic carcinoma higly suspected or its staging or restagingTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2017-004128-32-CZFakultní nemocnice Plzen200
Recruiting
Not Applicable
Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA)Prostate cancerJPRN-UMIN000037697Osaka University Graduate School of Medicine250